For adults with IgA nephropathy, discover how others manage IgAN. For additional Important Safety Information, including serious side effects, please see the Medication Guide at bit.ly/FILSPARI-med-guide. | FILSPARI® (sparsentan)
3:40
For adults with IgA nephropathy, discover how others manage IgAN. For additional Important Safety Information, including serious side effects, please see the Medication Guide at bit.ly/FILSPARI-med-guide. | FILSPARI® (sparsentan)
1.5M views8 months ago
FacebookFILSPARI® (sparsentan)
IgAN Management Into Practice: Evolving Guidelines & Targeted Therapies
13:36
IgAN Management Into Practice: Evolving Guidelines & Targeted Therapies
6 months ago
reachmd.com
A New Paradigm in IgAN Management—Advancing Clinical Practice in the Era of Therapeutic Expansion
9:11
A New Paradigm in IgAN Management—Advancing Clinical Practice in the Era of Therapeutic Expansion
4 months ago
reachmd.com
KDIGO updates IgAN guidelines for treatment and management | Vera Therapeutics, Inc. posted on the topic | LinkedIn
0:16
KDIGO updates IgAN guidelines for treatment and management | Vera Therapeutics, Inc. posted on the topic | LinkedIn
1 views7 months ago
linkedin.com
Biogen lance un essai de phase 3 pour le felzartamab dans une maladie rénale rare
Biogen lance un essai de phase 3 pour le felzartamab dans une maladie rénale rare
10 months ago
zonebourse.com
We are studying IgA nephropathy (IgAN), a serious autoimmune kidney disease that results from uncontrolled B cells. Our investigational approach aims to address the root cause of IgAN. Learn more about our strategy in IgAN and other conditions: https://www.vrtx.com/our-science/vertex-forward/#igan | Vertex
2:58
We are studying IgA nephropathy (IgAN), a serious autoimmune kidney disease that results from uncontrolled B cells. Our investigational approach aims to address the root cause of IgAN. Learn more about our strategy in IgAN and other conditions: https://www.vrtx.com/our-science/vertex-forward/#igan | Vertex
122 views3 months ago
FacebookVertex
Antibody-mediated rejection is a leading cause of kidney transplant failure. Felzartamab, an IgG1 monoclonal CD38 antibody, is under study for treating antibody-mediated rejection. Research findings are summarized in a new Quick Take video. https://nej.md/4dHQhsa | The New England Journal of Medicine
2:07
Antibody-mediated rejection is a leading cause of kidney transplant failure. Felzartamab, an IgG1 monoclonal CD38 antibody, is under study for treating antibody-mediated rejection. Research findings are summarized in a new Quick Take video. https://nej.md/4dHQhsa | The New England Journal of Medicine
1.4K viewsJul 14, 2024
FacebookThe New England Journal of Medicine
Biogen Inc.: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
10 months ago
finanznachrichten.de
Biogen lance une étude de phase 3 sur le Felzartamab pour le traitement du rejet tardif médié par les anticorps (AMR) chez les patients ayant subi une transplantation rénale.
Mar 11, 2025
zonebourse.com
2:22
𝗜𝗦𝗡 𝗩𝗜𝗗𝗘𝗢 𝗔𝗕𝗦𝗧𝗥𝗔𝗖𝗧 𝗦𝗘𝗥𝗜𝗘𝗦: Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy. 2025 from Kidney International https://www.kidney-international.org/article/S0085-2538(25)00488-0/fulltext #VideoAbstract by Suman Behera & Dilushi Wijayaratne | The International Society of Nephrology (ISN)
298 views3 months ago
FacebookThe International Society of Nephrology (ISN)
8:01
Emerging Evidence: IgAN Disease-Modifying Agents
2 views3 weeks ago
YouTubeReachMD
7:39
IgAN: Making Sense of New Treatments and Guidelines
157 views1 month ago
YouTubeGlomCon Foundation
Izalontamab Brengitecan Shows Promising Results in NSCLC with EGFR Exon20ins and HER2 Mutations | Aakash Desai, MD, MPH, FASCO posted on the topic | LinkedIn
1 views2 months ago
linkedin.com
41:32
Advancements in IgA Nephropathy
2.6K viewsMar 3, 2025
YouTubePeerView CME
19:45
The IgAN Treatment Pipeline: Complement Pathway
14K viewsFeb 6, 2025
YouTubeNational Kidney Foundation
17:39
The IgAN Treatment Pipeline: Pathogenesis Review
13.6K viewsFeb 6, 2025
YouTubeNational Kidney Foundation
14:52
The IgAN Treatment Pipeline: B-cell Pathway
3.1K viewsFeb 6, 2025
YouTubeNational Kidney Foundation
21:59
The IgAN Treatment Pipeline: Current Treatment Landscape
11.3K viewsFeb 6, 2025
YouTubeNational Kidney Foundation
1:29
Novel promising agents for the treatment of ITP
8.1K viewsJan 19, 2023
YouTubeVJHemOnc – Video Journal of Hematology & H…
2:44
SGLT2 Inhibitors Explained in 3 Minutes
47.3K viewsJan 6, 2019
YouTubeDrug Matters
3:53
Proteasome inhibitor drugs
26.1K viewsApr 4, 2017
YouTubeMyeloma UK
1:27
FIRAZYR (icatibant) Injection- hereditary angioedema
1K viewsJul 27, 2024
YouTubePharmacy Talk USA
9:45
Felzartamab Enters Phase 3 Trial for PMN
255 views10 months ago
YouTubeNephrology Times
8:31
Insights into the IgAN Patient Journey: From Diagnosis to Treatment
20 views5 months ago
YouTubeReachMD
1:00:37
Episode 2 - IgAN & FSGS Series: Management, Treatment & Recommendations for Future Research in IgAN
2.9K viewsJul 22, 2022
YouTubeKDIGO
5:07
Imugene gets FDA backing for azer-cel treatment
734 views5 months ago
YouTubeProactive Investors
0:39
A Breakthrough in IgA #Nephropathy: A Treatment that Lasts
770 views4 months ago
YouTubeHCPLive
9:10
Doctor PREDICTS Future Muscle Drugs: Bimagrumab, Follistatin, Orforglipron & More
25.7K views3 months ago
YouTubeDr. Alex Tatem
0:09
Breakthrough Therapy: Izalontamab for EGFR-Mutated Lung Cancer | MCQs Included!
181 views9 months ago
YouTubeMCQ Pedia
10:16
Meet Eric, diagnosed with IgAN at age 30
17.4K views6 months ago
YouTubeFILSPARI® (sparsentan)
See more
Static thumbnail place holder